Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN'S LYMPHOMA

Next Previous
Trial Profile

A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN'S LYMPHOMA

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SPC 2996 (Primary) ; Rituximab
  • Indications Follicular lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Santaris Pharma

Most Recent Events

  • 24 May 2012 Actual end date (7 Nov 2008) added as reported by European Clinical Trials Database record.
  • 24 May 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
  • 12 Jul 2011 This study has been completed in the Czech Republic (7 Nov 2008) and discontinued in Hungary (7 Nov 2008)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top